Biopharmaceutics is a pivotal field within the Food and Drug Administration's (FDA) purview, where the intersection of biology and pharmaceuticals takes center stage. This discipline focuses on the study of how drugs are absorbed, distributed, metabolized, and excreted by the body, with a keen eye on the biological factors influencing drug performance.
The FDA plays a crucial role in evaluating the safety and efficacy of biopharmaceuticals, ensuring that these innovative drugs meet rigorous standards before reaching the market. This involves a comprehensive assessment of the biological and chemical properties of these compounds, understanding their behavior in the human body, and predicting their therapeutic impact.
The dynamic landscape of biopharmaceutics aligns with the FDA's commitment to advancing public health by fostering the development of cutting-edge therapies. By staying at the forefront of scientific advancements, the FDA continues to navigate the evolving terrain of biopharmaceutics, contributing to the approval of novel, life-changing treatments that meet the highest standards of quality and effectiveness.
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami School of Medicine, United States
Title : Application of quality by design for pulmonary liposomes: Preliminary study to nano in-microparticle
Lucas Amaral Machado, University of Sao Paulo State – UNESP, Brazil
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary
Title : Tailored cellular environments to enable drug design
Lan Wang, Paretor LLC, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, InMedStar and Biona, Russian Federation
Title : Rational optimization of antibody–cyanine bioconjugates for targeted theranostic drug delivery and photo/sono activation
Amartya Sanyal, Ariel University, Israel
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : From in silico design to xenograft validation: Synthesis and evaluation of an Anti-EGFR antibody-derived peptide-drug conjugate for NSCLC
Pousali Mitra, Ariel University, Israel